823 related articles for article (PubMed ID: 31846984)
1. Emerging antibiotic resistance: carbapenemase-producing enterobacteria. Bad new bugs, still no new drugs.
Spera AM; Esposito S; Pagliano P
Infez Med; 2019 Dec; 27(4):357-364. PubMed ID: 31846984
[TBL] [Abstract][Full Text] [Related]
2. An update on the management of urinary tract infections in the era of antimicrobial resistance.
Bader MS; Loeb M; Brooks AA
Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
[TBL] [Abstract][Full Text] [Related]
3. Beta-lactamases in Enterobacteriaceae infections in children.
Moxon CA; Paulus S
J Infect; 2016 Jul; 72 Suppl():S41-9. PubMed ID: 27180312
[TBL] [Abstract][Full Text] [Related]
4. Extended-spectrum β-lactamase-producing and carbapenemase-producing Enterobacteriaceae.
Wilson H; Török ME
Microb Genom; 2018 Jul; 4(7):. PubMed ID: 30035710
[TBL] [Abstract][Full Text] [Related]
5. Emergence of carbapenem-resistant OXA-48 carbapenemase-producing Enterobacteriaceae in Tunisia.
Saïdani M; Hammami S; Kammoun A; Slim A; Boutiba-Ben Boubaker I
J Med Microbiol; 2012 Dec; 61(Pt 12):1746-1749. PubMed ID: 22918869
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.
Rodríguez-Baño J; Gutiérrez-Gutiérrez B; Machuca I; Pascual A
Clin Microbiol Rev; 2018 Apr; 31(2):. PubMed ID: 29444952
[TBL] [Abstract][Full Text] [Related]
7. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Sharma R; Park TE; Moy S
Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
[TBL] [Abstract][Full Text] [Related]
8. The ideal patient profile for new beta-lactam/beta-lactamase inhibitors.
Montravers P; Bassetti M
Curr Opin Infect Dis; 2018 Dec; 31(6):587-593. PubMed ID: 30299359
[TBL] [Abstract][Full Text] [Related]
9. Emergence of extended-spectrum β-lactamase (ESBL) and/or carbapenemase producing Enterobacteriaceae (CPE) and their antimicrobial resistance.
Koren J; Hubenakova Z; Drahovska H; Ozaee E; Markuskova B; Lichvarikova A
Bratisl Lek Listy; 2019; 120(12):935-940. PubMed ID: 31855054
[TBL] [Abstract][Full Text] [Related]
10. Notes from the Field: Carbapenem-resistant Enterobacteriaceae Producing OXA-48-like Carbapenemases--United States, 2010-2015.
Lyman M; Walters M; Lonsway D; Rasheed K; Limbago B; Kallen A
MMWR Morb Mortal Wkly Rep; 2015 Dec; 64(47):1315-6. PubMed ID: 26633574
[TBL] [Abstract][Full Text] [Related]
11. Emergence of carbapenem-resistant clinical Enterobacteriaceae isolates from a teaching hospital in Shanghai, China.
Hu F; Chen S; Xu X; Guo Y; Liu Y; Zhu D; Zhang Y
J Med Microbiol; 2012 Jan; 61(Pt 1):132-136. PubMed ID: 21903823
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Infections by OXA-48-Producing Enterobacteriaceae.
Stewart A; Harris P; Henderson A; Paterson D
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104282
[TBL] [Abstract][Full Text] [Related]
13. Evolution of antimicrobial resistance among Enterobacteriaceae (focus on extended spectrum β-lactamases and carbapenemases).
Lynch JP; Clark NM; Zhanel GG
Expert Opin Pharmacother; 2013 Feb; 14(2):199-210. PubMed ID: 23321047
[TBL] [Abstract][Full Text] [Related]
14. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
Bader MS; Loeb M; Leto D; Brooks AA
Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
[TBL] [Abstract][Full Text] [Related]
15. Management of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: current evidence and future prospects.
Sheu CC; Lin SY; Chang YT; Lee CY; Chen YH; Hsueh PR
Expert Rev Anti Infect Ther; 2018 Mar; 16(3):205-218. PubMed ID: 29402125
[TBL] [Abstract][Full Text] [Related]
16. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
17. 3-
Lee T; Lee S; Kim MK; Ahn JH; Park JS; Seo HW; Park KH; Chong Y
ACS Infect Dis; 2024 May; 10(5):1624-1643. PubMed ID: 38652574
[TBL] [Abstract][Full Text] [Related]
18. The management of multidrug-resistant Enterobacteriaceae.
Bassetti M; Peghin M; Pecori D
Curr Opin Infect Dis; 2016 Dec; 29(6):583-594. PubMed ID: 27584587
[TBL] [Abstract][Full Text] [Related]
19. Higher third-generation cephalosporin prescription proportion is associated with lower probability of reducing carbapenem use: a nationwide retrospective study.
Muller A; Bertrand X; Rogues AM; Péfau M; Alfandari S; Gauzit R; Dumartin C; Gbaguidi-Haore H;
Antimicrob Resist Infect Control; 2018; 7():11. PubMed ID: 29387345
[TBL] [Abstract][Full Text] [Related]
20. New Delhi Metallo-beta lactamase (NDM-1) in Enterobacteriaceae: treatment options with carbapenems compromised.
Deshpande P; Rodrigues C; Shetty A; Kapadia F; Hedge A; Soman R
J Assoc Physicians India; 2010 Mar; 58():147-9. PubMed ID: 20848811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
